|
1
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rumgay H, Arnold M, Ferlay J, Lesi O,
Cabasag CJ, Vignat J, Laversanne M, McGlynn KA and Soerjomataram I:
Global burden of primary liver cancer in 2020 and predictions to
2040. J Hepatol. 77:1598–1606. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rimassa L, Finn RS and Sangro B:
Combination immunotherapy for hepatocellular carcinoma. J Hepatol.
79:506–515. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kudo M: Treatment decision-making in
unresectable hepatocellular carcinoma: Importance of understanding
the different response patterns between IO plus Anti-VEGF and IO
plus IO Regimens. Liver Cancer. 14:119–126. 2025.PubMed/NCBI
|
|
5
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tomonari T, Tani J, Sato Y, Tanaka H,
Tanaka T, Taniguchi T, Kawano Y, Morishita A, Okamoto K, Sogabe M,
et al: Clinical features and outcomes of conversion therapy in
patients with unresectable hepatocellular carcinoma. Cancers
(Basel). 15:52212023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kikuchi T, Takeuchi Y, Nouso K, Kariyama
K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake
H, et al: Predictive factors for transition to conversion therapy
in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Liver Int. 44:1456–1463. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kudo M, Aoki T, Ueshima K, Tsuchiya K,
Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, et al:
Achievement of complete response and drug-free status by
atezolizumab plus bevacizumab combined with or without curative
conversion in patients with transarterial
chemoembolization-unsuitable, intermediate-stage hepatocellular
carcinoma: A multicenter proof-of-concept study. Liver Cancer.
12:321–338. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ochi H, Kurosaki M, Joko K, Mashiba T,
Tamaki N, Tsuchiya K, Marusawa H, Tada T, Nakamura S, Narita R, et
al: Usefulness of neutrophil-to-lymphocyte ratio in predicting
progression and survival outcomes after atezolizumab-bevacizumab
treatment for hepatocellular carcinoma. Hepatol Res. 53:61–71.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cholongitas E, Papatheodoridis GV, Vangeli
M, Terreni N, Patch D and Burroughs AK: Systematic review: The
model for end-stage liver disease-should it replace Child-Pugh's
classification for assessing prognosis in cirrhosis? Aliment
Pharmacol Ther. 22:1079–1089. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hiraoka A, Michitaka K, Kumada T, Izumi N,
Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M,
et al: Validation and potential of albumin-bilirubin grade and
prognostication in a nationwide survey of 46,681 hepatocellular
carcinoma patients in Japan: The need for a more detailed
evaluation of hepatic function. Liver Cancer. 6:325–336. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 practice
guidance by the American association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakagawa M, Inoue M, Ogasawara S, Maruta
S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, et al:
Clinical effects and emerging issues of atezolizumab plus
bevacizumab in patients with advanced hepatocellular carcinoma from
Japanese real-world practice. Cancer. 129:590–599. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aoki T, Kudo M, Nishida N, Ueshima K,
Tsuchiya K, Tada T, Morita M, Chishina H, Takita M, Hagiwara S, et
al: Proposal of discontinuation criteria of atezolizumab plus
bevacizumab after curative conversion therapy for unresectable
early-to-intermediate-stage hepatocellular carcinoma: A multicenter
proof-of-concept study. J Gastroenterol. 60:738–753. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Campani C, Bamba-Funck J, Campion B,
Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E,
Evain M, et al: Baseline ALBI score and early variation of serum
AFP predicts outcomes in patients with HCC treated by
atezolizumab-bevacizumab. Liver Int. 43:708–717. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuzuya T, Kawabe N, Muto H, Tachi Y, Ukai
T, Wada Y, Komura G, Nakano T, Tanaka H, Nakaoka K, et al:
Characteristics and prognosis of patients with advanced
hepatocellular carcinoma treated with atezolizumab/bevacizumab
combination therapy who achieved complete response. Curr Oncol.
31:6218–6231. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shindoh J, Matsumura M, Okubo S, Okada T,
Hashimoto M, Nakamura M and Ohtsuka M: A questionnaire survey to
explore the current treatment policies adopted for patients with
advanced hepatocellular carcinoma at board-certified HPB training
institutions in Japan: A JSHBPS project study 2023, Part 1. J
Hepatobiliary Pancreat Sci. 32:360–373. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Niizeki T, Tokunaga T, Takami Y, Wada Y,
Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, et al:
Comparison of efficacy and safety of atezolizumab plus bevacizumab
and lenvatinib as first-line therapy for unresectable
hepatocellular carcinoma: A propensity score matching analysis.
Target Oncol. 17:643–653. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kudo M: A novel treatment strategy for
patients with intermediate-stage HCC who are not suitable for TACE:
Upfront systemic therapy followed by curative conversion. Liver
Cancer. 10:539–544. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang MD, Xu XJ, Wang KC, Diao YK, Xu JH,
Gu LH, Yao LQ, Li C, Lv GY and Yang T: Conversion therapy for
advanced hepatocellular carcinoma in the era of precision medicine:
Current status, challenges and opportunities. Cancer Sci.
115:2159–2169. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kudo M: Sequential therapy for
hepatocellular carcinoma after failure of atezolizumab plus
bevacizumab combination therapy. Liver Cancer. 10:85–93. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimose S, Iwamoto H, Shirono T, Tanaka M,
Niizeki T, Kajiwara M, Itano S, Yano Y, Matsugaki S, Moriyama E, et
al: The impact of curative conversion therapy aimed at a
cancer-free state in patients with hepatocellular carcinoma treated
with atezolizumab plus bevacizumab. Cancer Med. 12:12325–12335.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishihara N, Komatsu S, Sofue K, Ueshima E,
Yano Y, Fujishima Y, Ishida J, Kido M, Gon H, Fukushima K, et al:
Association between tumor morphology and efficacy of atezolizumab
plus bevacizumab for advanced hepatocellular carcinoma. Hepatol
Res. 54:773–780. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Komatsu S, Fukumoto T, Demizu Y, Miyawaki
D, Terashima K, Niwa Y, Mima M, Fujii O, Sasaki R, Yamada I, et al:
The effectiveness of particle radiotherapy for hepatocellular
carcinoma associated with inferior vena cava tumor thrombus. J
Gastroenterol. 46:913–920. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Komatsu S, Fukumoto T, Demizu Y, Miyawaki
D, Terashima K, Sasaki R, Hori Y, Hishikawa Y, Ku Y and Murakami M:
Clinical results and risk factors of proton and carbon ion therapy
for hepatocellular carcinoma. Cancer. 117:4890–4904. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Komatsu S, Terashima K, Ishihara N, Matsuo
Y, Kido M, Yanagimoto H, Toyama H, Tokumaru S, Okimoto T and
Fukumoto T: Novel concept of ‘sequential particle radiotherapy’
with atezolizumab plus bevacizumab for hepatocellular carcinoma
with portal vein tumor thrombus. Surg Today. 54:972–976. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takakusagi S, Tanaka H, Naganuma A,
Kakizaki S, Shibuya K, Ohno T, Takagi H and Uraoka T: Two cases of
hepatocellular carcinoma successfully treated by carbon ion
radiotherapy after atezolizumab plus bevacizumab treatment. Clin J
Gastroenterol. 16:407–415. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
European Association for the Study of the
Liver, . EASL clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang K, Zhu H, Yu H, Cheng Y, Xiang Y,
Cheng Z, Li Y, Li T, Wang D, Zhu Z and Cheng S: Early Experience of
TACE combined with atezolizumab plus bevacizumab for patients with
intermediate-stage hepatocellular carcinoma beyond up-to-seven
criteria: A multicenter, single-arm study. J Oncol.
2023:63530472023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao C, Xiang Z, Li M, Wang H, Liu H, Yan
H and Huang M: Transarterial chemoembolization combined with
atezolizumab plus bevacizumab or lenvatinib for unresectable
hepatocellular carcinoma: A propensity score matched study. J
Hepatocell Carcinoma. 10:1195–1206. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kudo M, Ueshima K, Saeki I, Ishikawa T,
Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, et al: A
phase 2, prospective, multicenter, single-arm trial of
transarterial chemoembolization therapy in combination strategy
with lenvatinib in patients with unresectable intermediate-stage
hepatocellular carcinoma: TACTICS-L trial. Liver Cancer. 13:99–112.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Allaire M, Goumard C, Lim C, Le Cleach A,
Wagner M and Scatton O: New frontiers in liver resection for
hepatocellular carcinoma. JHEP Rep. 2:1001342020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schulz-Ertner D and Tsujii H: Particle
radiation therapy using proton and heavier ion beams. J Clin Oncol.
25:953–964. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Katsuya G, Kato H, Yasuda S, Tsuji H,
Yamada S, Haruyama Y, Kobashi G, Ebner DK, Okada NN, Makishima H,
et al: Progressive hypofractionated carbon-ion radiotherapy for
hepatocellular carcinoma: Combined analyses of 2 prospective
trials. Cancer. 123:3955–3965. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH,
Park B and Park JW: Proton beam radiotherapy vs. radiofrequency
ablation for recurrent hepatocellular carcinoma: A randomized phase
III trial. J Hepatol. 74:603–612. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yoo GS, Yu JI and Park HC: Proton therapy
for hepatocellular carcinoma: Current knowledges and future
perspectives. World J Gastroenterol. 24:3090–3100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee SU and Kim TH: Current evidence and
the potential role of proton beam therapy for hepatocellular
carcinoma. Clin Mol Hepatol. 29:958–968. 2023. View Article : Google Scholar : PubMed/NCBI
|
